Related Experiment Videos

Factors influencing cardiovascular risk following termination of glucocorticoid therapy for nephrotic syndrome

Akio Nakamura1, Ryo Niimi, Kumiko Kurosaki

  • 1Department of Paediatrics, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo, 173-8605, Japan. akio@med.teikyo-u.ac.jp

Clinical and Experimental Nephrology
|July 20, 2010
PubMed

Insights

Children with nephrotic syndrome retaining excess weight after glucocorticoid therapy showed higher cardiovascular risk. This was linked to increased medication dosage, duration, and elevated cholesterol levels, indicating potential hyperlipidemia.

Area of Science:

  • Pediatric Endocrinology
  • Nephrology
  • Cardiovascular Risk Assessment

Background:

  • Nephrotic syndrome is a kidney disorder often treated with glucocorticoids.
  • Glucocorticoid therapy can lead to excess weight retention.
  • Identifying cardiovascular risks post-treatment is crucial for long-term health.

Purpose of the Study:

  • To investigate cardiovascular risk factors in children with nephrotic syndrome who retain excess weight after glucocorticoid therapy.
  • To determine the association between weight retention, glucocorticoid exposure, and lipid profiles.

Main Methods:

  • Retrospective study of 30 Japanese children treated for nephrotic syndrome and 32 controls.
  • Categorization into weight retention or reduction groups based on BMI z-scores post-glucocorticoid therapy.
  • Evaluation of BMI z-scores, age, gender, blood pressure, serum total cholesterol, and glucocorticoid dose/duration.

Main Results:

  • The weight retention group had significantly higher glucocorticoid dose and duration of exposure.
  • Elevated serum total cholesterol (T-cho) levels were observed in the retention group compared to control and reduction groups.
  • Logistic regression indicated a significantly higher odds ratio for elevated T-cho in the retention group.

Conclusions:

  • Excess weight retention in children with nephrotic syndrome post-glucocorticoid therapy is associated with higher glucocorticoid exposure.
  • Hyperlipidemia, indicated by elevated cholesterol, is linked to weight retention and may increase cardiovascular risk.
  • Further research is needed to mitigate these risks in pediatric patients.
Abstract

Related Concept Videos

Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of fluid...
Nephrotic Syndrome III : Nursing Management01:24

Nephrotic Syndrome III : Nursing Management

Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of fluid...
Factors Affecting Renal Clearance: Renal Impairment01:17

Factors Affecting Renal Clearance: Renal Impairment

Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...